Adjuvant versus salvage radiotherapy for high-risk prostate cancer patients

Seminars in Radiation Oncology

Volumn 23, Issue 3, 2013, Pages 215-221

  King, Christopher R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; COMPARATIVE STUDY; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY;

EID: 84878848724     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.01.009     Document Type: Review

References (18)

1. Cotter S.E., Chen M.H., Moul J.W., et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 2011, 117:3925-3932.
2. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25:2035-2041.
3. Bolla M., van Poppel H., Tombal B., et al. Radiation oncology and Genito-urinary groups. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012, 380:2018-2027.
4. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
5. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006, 296:2329-2335.
6. Parker C., Sydes M.R., Catton C., et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007, 99:1376-1379.
7. Richaud P., Sargos P., Henriques de Figueiredo B., et al. Postoperative radiotherapy of prostate cancer (GETUG-17). Cancer Radiother 2010, 14:500-503.
8. Trans-Tasman Radiation Oncology Group: (Trog 08-03) RAVES trial: Radiotherapy-Adjuvant versus early salvage.
9. King C.R. The timing of salvage radiotherapy after radical prostatectomy: A systematic review. Int J Radiat Oncol Biol Phys 2012, 84:104-111.
10. Cox J.D., Gallagher M.J., Hammond E.H., et al. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999, 17:1155.
11. Michalski J.M., Lawton C., El Naqa I., et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 76:361-368.
12. Lawton C.A., Desilvio M., Roach M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/Radiation interactions. Int J Radiat Oncol Biol Phys 2007, 69:646-655.
13. Pommier P., Chabaud S., Lagrange J.L., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma?. Preliminary results of GETUG-01. J Clin Oncol 2007, 25:5366-5373.
14. Spiotto M.T., Hancock S.L., King C.R. Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 2007, 69:54-61.
15. King C.R., Presti J.C., Gill H., et al. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys 2004, 59:341-347.
16. Ost P., Cozzarini C., De Meerleer G., et al. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2012, 83:960-965.
17. Shipley W.U., Hunt D., Lukka H.R., et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (αAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease and elevated PSA levels. J Clin Oncol 2011, (suppl 7):29. abstract 1.
18. Feng M., Hanlon A.L., Pisansky T.M., et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:1417-1423.